Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 11/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17809595 | 1.00 | USP30 (0.48) | USP30CREBBPRETPIK3CDPIK3R1 | |
| SCHEMBL17809641 | 1.00 | USP30 (0.48) | USP30CREBBPRETPIK3CDPIK3R1 | |
| SCHEMBL17806311 | 0.86 | USP30 (0.48) | USP30RETPIK3CDPIK3R1 | |
| SCHEMBL17806251 | 0.86 | USP30 (0.48) | USP30RETPIK3CDPIK3R1 | |
| SCHEMBL17806334 | 0.86 | USP30 (0.48) | USP30RETPIK3CDPIK3R1 | |
| SCHEMBL17809747 | 0.82 | USP30 (0.50) | USP30CREBBPRETPIK3CDPIK3R1 | |
| SCHEMBL17809646 | 0.79 | USP30 (0.58) | USP30CREBBPRETPIK3CDPIK3R1 | |
| SCHEMBL17795237 | 0.79 | CREBBP (0.47) | CREBBP | |
| SCHEMBL17809760 | 0.79 | CREBBP (0.47) | CREBBP | |
| SCHEMBL17795234 | 0.79 | CREBBP (0.47) | CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224258-B1 | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | USP30 2156/4885CREBBP 6/4885RET 855/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | USP30 2156/4885CREBBP 6/4885RET 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.